Israel Englander’s Summit Therapeutics SMMT Stock Holding History

Israel Englander’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-77,000	Closed	-$1.35M	–	6331
2025 Q4	$1.35M	Buy	+77,000	New	+$1.45M	﹤0.01%	4256
2025 Q3	–	Sell	-84,000	Closed	-$1.79M	–	6431
2025 Q2	$1.79M	Sell	84,000 -17,000	-17%	-$388K	﹤0.01%	3979
2025 Q1	$1.95M	Buy	101,000 +86,000	+573%	+$1.73M	﹤0.01%	3805
2024 Q4	$268K	Sell	15,000 -400	-3%	-$7.75K	﹤0.01%	5131
2024 Q3	$337K	Buy	+15,400	New	+$215K	﹤0.01%	5118

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Israel Englander's SMMT Position: Q2 2026 in Review

Israel Englander increased its Summit Therapeutics (SMMT) stake by 1,760% in Q2 2026, buying an estimated $39.4M and bringing the position to 2,349,081 shares worth $34.2M. The position accounts for 0.01% of the portfolio, ranked #1172.

Israel Englander first reported a position in SMMT in Q4 2016 and has held it in 22 quarters since. The position peaked at $36.6M in Q4 2024. 241 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Israel Englander held 2,349,081 shares of Summit Therapeutics worth $34.2M as of Q2 2026.
Israel Englander bought 2,222,808 Summit Therapeutics shares in Q2 2026, an estimated $39.4M.
Summit Therapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1172 holding.
Israel Englander first reported a position in Summit Therapeutics in Q4 2016 and has held it in 22 quarters since.
Israel Englander's Summit Therapeutics position peaked at $36.6M in Q4 2024.
241 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.